ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase II for Lung Cancer. According to GlobalData, Phase II drugs for Lung Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ZEN-3694’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZEN-3694 is under development for the treatment of metastatic castration-resistant prostate cancer, acute myelocytic leukemia, solid tumors such as epithelial ovarian cancer, lung cancer, colon cancer, lymphoma, pancreatic cancer, melanoma, NUT midline carcinoma, triple negative breast cancer, ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma. The drug candidate is administered through oral route. The drug candidate acts by targeting BRD2, BRD3, BRD4 and BRDT.
Zenith Epigenetics overview
Zenith Epigenetics, a subsidiary of Zenith Capital Corp, is a clinical-stage biotechnology company that focuses on the discovery and development of small molecules for the inhibition of BET bromodomains. The company’s lead product ZEN-3694 is a BET inhibitor intended for the treatment of solid tumors, including metastatic prostate cancer. Its platform integrates structural biology, medicinal chemistry and modeling with biochemical and cell-based assays. The company has a presence in Canada and the US. Zenith Epigenetics is headquartered in Calgary, Alberta, Canada.
For a complete picture of ZEN-3694’s drug-specific PTSR and LoA scores, buy the report here.